A tetra-substituted GHRH(1-29) analog. The four substitutions resist enzymatic degradation. The DAC (Drug Affinity Complex) variant adds a reactive linker that forms a covalent bond with circulating albumin, extending half-life from minutes to roughly one to two weeks — which converts pulsatile GH release into a sustained elevation, a pharmacologically significant departure from normal physiology.
Early-phase human pharmacokinetic work exists from the original developer, showing sustained GH and IGF-1 elevation. Development was not carried through to approval. There are no adequate controlled trials supporting efficacy for any clinical outcome.
Not FDA-approved. No USP monograph. Placed on the FDA's 503A Category 2 list, then removed in April 2026 after the nomination was withdrawn — but not moved to Category 1. It occupies a regulatory grey zone: neither expressly permitted for compounding nor expressly prohibited. Prohibited in sport (WADA S2).
Sustained rather than pulsatile GH elevation is the central unknown; chronic GH-axis stimulation is associated with insulin resistance, oedema, arthralgia, and theoretical malignancy-promotion concerns. Long-term human safety is uncharacterised.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.